Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2014

01.10.2014 | Original Article

Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer

verfasst von: Deniz Tural, Fatih Selcukbiricik, Özcan Yıldız, Olgun Elcin, Sibel Erdamar, Sabri Güney, Fuat Demireli, Evin Büyükünal, Süheyla Serdengeçti

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The study populations of previous preoperative chemoradiotherapy (pre-CRT) studies have consisted of mixed clinical stages, such as cT3-cT4 and/or cN positive. For this reason, it has not been possible to demonstrate whether pre-CRT is of benefit for individual subgroups.

Methods

The medical records of 137 rectal cancer patients with clinical stage T3, N0 disease who received either pre-CRT or postoperative chemoradiotherapy (post-CRT) between 2002 and 2011 were retrospectively analyzed. The regimen of pre-CRT consisted of slow fluorouracil (5FU) infusion and that of post-CRT consisted of bolus 5FU and leucovorin concurrent with radiation.

Results

Following pre-CRT, significant downstaging was achieved. However, administration of pre-CRT did not influence the type of surgical resection in tumours ≤5 cm distant from the anal verge (p = 0.14). Pathological complete response was achieved in 16 % of the patients in the pre-CRT group. The local recurrence rate (LRR) at 5 years was 5.7 % in the pre-CRT and 11.1 % in the post-CRT groups (p = 0.04). The distant recurrence rate (DRR) at 5 years was 76 % and 77 % in the pre-CRT and post-CRT groups, respectively (p = 0.1). Overall survival was similar in two groups (74.8 % vs. 75.3 %, p = 0.3).

Conclusions

The treatment of stage T3, N0 rectal cancer patients with pre-CRT followed by surgery decreased LRR, but did not improve DRR or OS as compared with surgery followed by post-CRT in our patient cohort.
Literatur
1.
Zurück zum Zitat National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer.JAMA1990; 264:1444–1450 National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer.JAMA1990; 264:1444–1450
2.
Zurück zum Zitat Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH et al (1999) T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 3:642–647PubMedCrossRef Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH et al (1999) T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 3:642–647PubMedCrossRef
3.
Zurück zum Zitat Picon AI, Moore HG, Sternberg SS, Minsky BD, Paty PB, Blumberg D et al (2003) Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis 18:487–492PubMedCrossRef Picon AI, Moore HG, Sternberg SS, Minsky BD, Paty PB, Blumberg D et al (2003) Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis 18:487–492PubMedCrossRef
4.
Zurück zum Zitat Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC (1999) Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167–173PubMedCrossRef Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC (1999) Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167–173PubMedCrossRef
5.
Zurück zum Zitat Steel MC, Woods R, Mackay JM, Chen F (2002) Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg. 72:483–487PubMedCrossRef Steel MC, Woods R, Mackay JM, Chen F (2002) Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg. 72:483–487PubMedCrossRef
6.
Zurück zum Zitat Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O’Connell MJ, Begovic M et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22:1785–1796PubMedCrossRef Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O’Connell MJ, Begovic M et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22:1785–1796PubMedCrossRef
7.
Zurück zum Zitat Park IJ, Kim HC, Yu CS, Kim TW, Jang SJ, Kim JC et al (2008) Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol 15:519–525PubMedCrossRef Park IJ, Kim HC, Yu CS, Kim TW, Jang SJ, Kim JC et al (2008) Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol 15:519–525PubMedCrossRef
8.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, The German Rectal Cancer Study Group et al (2004) Preoperative versus postoperative CRT for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, The German Rectal Cancer Study Group et al (2004) Preoperative versus postoperative CRT for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef
9.
Zurück zum Zitat Bosset JF, Collette L, Calais G (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114PubMedCrossRef Bosset JF, Collette L, Calais G (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114PubMedCrossRef
10.
Zurück zum Zitat Guillem JG, Díaz-González JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA et al (2008) T3N0 rectal cancer: potential overtreatment with preoperative CRT ıs warranted. J Clin Oncol 26:368–373PubMedCrossRef Guillem JG, Díaz-González JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA et al (2008) T3N0 rectal cancer: potential overtreatment with preoperative CRT ıs warranted. J Clin Oncol 26:368–373PubMedCrossRef
11.
Zurück zum Zitat Hildebrandt U, Feifel G (1985) Preoperative staging of rectal cancer by intrarectal ultrasound. Dis Colon Rectum 28:42–46PubMedCrossRef Hildebrandt U, Feifel G (1985) Preoperative staging of rectal cancer by intrarectal ultrasound. Dis Colon Rectum 28:42–46PubMedCrossRef
12.
Zurück zum Zitat Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP et al (1999) Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 211:215–222PubMedCrossRef Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP et al (1999) Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 211:215–222PubMedCrossRef
13.
Zurück zum Zitat Greene FL, Page DL, Fleming ID (2002) American Joint Committee on Cancer staging manual, 6th edn. Springer, PhiladelphiaCrossRef Greene FL, Page DL, Fleming ID (2002) American Joint Committee on Cancer staging manual, 6th edn. Springer, PhiladelphiaCrossRef
14.
Zurück zum Zitat Birgisson Helgi, Påhlman Lars, Gunnarsson Ulf (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol 23:8697–8705PubMedCrossRef Birgisson Helgi, Påhlman Lars, Gunnarsson Ulf (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol 23:8697–8705PubMedCrossRef
15.
Zurück zum Zitat Peeters KC, Marijnen CA, Nagtegaal ID (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701PubMedCrossRef Peeters KC, Marijnen CA, Nagtegaal ID (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701PubMedCrossRef
16.
Zurück zum Zitat Sebag-Montefiore D, Stephens RJ, Steele R (2009) Preoperative radiotherapy versus selective postoperative CRT in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820PubMedCrossRefPubMedCentral Sebag-Montefiore D, Stephens RJ, Steele R (2009) Preoperative radiotherapy versus selective postoperative CRT in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820PubMedCrossRefPubMedCentral
17.
Zurück zum Zitat Bosset JF, Calais G, Mineur L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 23:5620–5627PubMedCrossRef Bosset JF, Calais G, Mineur L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 23:5620–5627PubMedCrossRef
18.
Zurück zum Zitat Gérard JP, Conroy T, Bonnetain F (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef Gérard JP, Conroy T, Bonnetain F (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef
19.
Zurück zum Zitat Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M (2006) Longterm results of a randomized trial comparing preoperative shortcourse radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223PubMedCrossRef Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M (2006) Longterm results of a randomized trial comparing preoperative shortcourse radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223PubMedCrossRef
20.
Zurück zum Zitat Gérard JP, Conroy T, Bonnetain F (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef Gérard JP, Conroy T, Bonnetain F (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef
21.
Zurück zum Zitat Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009: CD006041 Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009: CD006041
22.
Zurück zum Zitat Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124PubMedCrossRefPubMedCentral Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124PubMedCrossRefPubMedCentral
23.
Zurück zum Zitat Lombardi R, Cuicchi D, Pinto C, Di Fabio F, Iacopino B, Neri S et al (2010) Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol 17:838–845PubMedCrossRef Lombardi R, Cuicchi D, Pinto C, Di Fabio F, Iacopino B, Neri S et al (2010) Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol 17:838–845PubMedCrossRef
24.
Zurück zum Zitat Kao PS, Chang SC, Wang LW, Lee RC, Liang WY, Lin TC, et al (2010) The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol 102:771-777PubMedCrossRef Kao PS, Chang SC, Wang LW, Lee RC, Liang WY, Lin TC, et al (2010) The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol 102:771-777PubMedCrossRef
25.
Zurück zum Zitat Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J et al (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology 232:773–783PubMedCrossRef Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J et al (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology 232:773–783PubMedCrossRef
Metadaten
Titel
Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer
verfasst von
Deniz Tural
Fatih Selcukbiricik
Özcan Yıldız
Olgun Elcin
Sibel Erdamar
Sabri Güney
Fuat Demireli
Evin Büyükünal
Süheyla Serdengeçti
Publikationsdatum
01.10.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0636-4

Weitere Artikel der Ausgabe 5/2014

International Journal of Clinical Oncology 5/2014 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.